85 Figure 3 Distribution of abnormalities measured with both the method of levels (MLe) and the method of limits (MLi), with only MLe, only MLi or both detected as normal for (A) the cold detection threshold (CDT) and (B) the warm detection threshold (WDT). CDT and WDT were abnormal in at least one foot in 42% and 23% of patients with sarcoidosis and SFN, respectively. One healthy control showed abnormal CDT and another showed abnormal WDT at one foot. CPT and HPT were abnormal in at least one foot in 4% and 8% of patients with sarcoidosis and SFN, respectively. Four healthy controls showed one abnormal pain parameter in at least one foot. Table 3 shows the percentage abnormalities for each parameter per group, measured at both feet. MLe showed by far the most abnormalities in patients with sarcoidosis without SFN and healthy controls. According to the new Besta criteria,7 60% of patients with sarcoidosis and SFN showed abnormal QST. However, patients with sarcoidosis without SFN and healthy controls also showed large numbers of abnormal QST results, viz. 47% and 55%, respectively. All TTT parameters at both feet resulted in even larger numbers of abnormalities in all three groups, with even less discriminative power (TTT feet all). Since MLe showed the most abnormalities in healthy controls, we investigated whether the performance of all TTT parameters would improve without MLe. As seen in Table 4, “TTT feet without MLe” was better able to discriminate between the groups than “TTT feet all”. 5 89 5
RkJQdWJsaXNoZXIy MjY0ODMw